Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Headache|August 7, 2021
STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patientsTimothy R Smith, Paul Winner, Sheena K Aurora, et al.
The Journal of Clinical Psychiatry|July 2, 2020
The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy AdultsStephen B Shrewsbury, Jasna Hocevar-Trnka, Kelsey H Satterly, et al.
International Journal of Toxicology|May 5, 2011
Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophyPeter Sazani, Kirk P Van Ness, Doreen L Weller, et al.
International Journal of Toxicology|May 5, 2011
Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx micePeter Sazani, Kirk P Van Ness, Doreen L Weller, et al.
Headache|May 27, 2024
Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraineRima M Dafer, Gretchen E Tietjen, John F Rothrock, et al.
Mayo Clinic Proceedings|April 7, 2004
Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trialJames P Kemp, Scott Osur, Stephen B Shrewsbury, et al.
Nucleic Acid Therapeutics|July 20, 2012
Clinical expert panel on monitoring potential lung toxicity of inhaled oligonucleotides: consensus points and recommendationsEric W Alton, Homer A Boushey, Holger Garn, et al.
Lancet (London, England)|July 26, 2011
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studySebahattin Cirak, Virginia Arechavala-Gomeza, Michela Guglieri, et al.
Pageof 3